CN Patent

CN113636979B — 一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用

Assigned to Tianjin University of Technology · Expires 2023-06-13 · 3y expired

What this patent protects

本发明提供一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用，本发明的奥拉帕尼与富马酸共晶晶型α具备高的口服生物利用度且其引湿性低、稳定性高、可压片性好，可以开发疗效更好、副作用更小的奥拉帕尼改良型制剂。本发明的奥拉帕尼与富马酸共晶晶型α的制备方法工艺简单，结晶过程易于控制，重现性好，适用于工业化生产，在制备预防和/或治疗癌症的药物中具有广阔的应用前景。

USPTO Abstract

本发明提供一种奥拉帕尼与富马酸共晶晶型α及其制备方法与应用，本发明的奥拉帕尼与富马酸共晶晶型α具备高的口服生物利用度且其引湿性低、稳定性高、可压片性好，可以开发疗效更好、副作用更小的奥拉帕尼改良型制剂。本发明的奥拉帕尼与富马酸共晶晶型α的制备方法工艺简单，结晶过程易于控制，重现性好，适用于工业化生产，在制备预防和/或治疗癌症的药物中具有广阔的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN113636979B
Jurisdiction
CN
Classification
—
Expires
2023-06-13
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin University of Technology
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.